Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation

被引:107
作者
Klint, P
Kanda, S
Kloog, Y
Claesson-Welsh, L
机构
[1] BMC, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden
[2] Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan
[3] Tel Aviv Univ, Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel
关键词
FGF receptor; endothelial cell; differentiation; Src; Ras; Raf;
D O I
10.1038/sj.onc.1202680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have examined fibroblast growth factor (FGF) receptor-1 mediated signal transduction in differentiation of endothelial cells (EC). The activated FGFR-1 couples to Ras through two adaptor proteins, FRS2 and Shc. In FGF-2 treated proliferating EC, FRS2 as well as She are tyrosine phosphorylated and interact with Grb2, In contrast, in FGF-2 treated differentiating cells, Shc, but not FRS2, is engaged in Grb2-interactions, Sustained MAP kinase activity has previously been implicated in differentiation. In FGF stimulated proliferating and differentiating endothelial cells, the MAP kinase Erk2 is activated in a sustained manner. Inhibition of MEK and MAP kinase activity by PD98059 treatment of cells, still allows EC tube formation, The FGFR-1 mediates activation of protein kinase C (PKC) through direct binding and activation of phospholipase C-gamma (PLC-gamma), and has also been shown to activate the cytoplasmic tyrosine kinase Src. Treatment of the cells with the PKC inhibitor bisindolylmaleimide does not prevent tube formation. In contrast, Src kinase activity is prerequisite for EC differentiation, since treatment of the cells with PP1, a Src family specific inhibitor, abrogates tube formation. In differentiating EC, FGF-2 induces complex formation between Src and focal adhesion kinase (FAK). These data indicate that the Ras pathway is initiated via She or FRS2. dependent on the cellular program. Blocking the function of Src family kinases, attenuates differentiation.
引用
收藏
页码:3354 / 3364
页数:11
相关论文
共 47 条
  • [1] THE FGF FAMILY OF GROWTH-FACTORS AND ONCOGENES
    BASILICO, C
    MOSCATELLI, D
    [J]. ADVANCES IN CANCER RESEARCH, 1992, 59 : 115 - 165
  • [2] THE HEPARIN-BINDING (FIBROBLAST) GROWTH-FACTOR FAMILY OF PROTEINS
    BURGESS, WH
    MACIAG, T
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 : 575 - 606
  • [3] Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?
    Cox, AD
    Der, CJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1333 (01): : F51 - F71
  • [4] Integrinαvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
    Eliceiri, BP
    Klemke, R
    Strömblad, S
    Cheresh, DA
    [J]. JOURNAL OF CELL BIOLOGY, 1998, 140 (05) : 1255 - 1263
  • [5] ANGIOGENIC FACTORS
    FOLKMAN, J
    KLAGSBRUN, M
    [J]. SCIENCE, 1987, 235 (4787) : 442 - 447
  • [6] FOLKMAN J, 1986, CANCER RES, V46, P467
  • [7] A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3
    Gotoh, N
    Tojo, A
    Shibuya, M
    [J]. EMBO JOURNAL, 1996, 15 (22) : 6197 - 6204
  • [8] Dislodgment and accelerated degradation of Ras
    Haklai, R
    Weisz, MG
    Elad, G
    Paz, A
    Marciano, D
    Egozi, Y
    Ben-Baruch, G
    Kloog, Y
    [J]. BIOCHEMISTRY, 1998, 37 (05) : 1306 - 1314
  • [9] Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation
    Hanke, JH
    Gardner, JP
    Dow, RL
    Changelian, PS
    Brissette, WH
    Weringer, EJ
    Pollok, K
    Connelly, PA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) : 695 - 701
  • [10] IDENTIFICATION OF RAS FARNESYLTRANSFERASE INHIBITORS BY MICROBIAL SCREENING
    HARA, M
    AKASAKA, K
    AKINAGA, S
    OKABE, M
    NAKANO, H
    GOMEZ, R
    WOOD, D
    UH, M
    TAMANOI, F
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) : 2281 - 2285